Themis Medicare Limited (THEMISMED.BO)
BSE · INR · Healthcare · Drug Manufacturers - Specialty & Generic
₹95.60 (+4.25%) as of
Key statistics
- Market cap
- 8.80B
- P/E (TTM)
- 22.08
- EPS (TTM)
- 4.33
- Dividend yield
- 0.55%
- 52-week range
- 65.00 – 141.05
- Beta
- 0.55
- Revenue (TTM)
- 3.32B
- Profit margin
- 12.06%
- Volume
- 4.14k
About Themis Medicare Limited
Themis Medicare Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in India and internationally. It provides active pharmaceutical ingredients (APIs) and formulations used in various therapeutic areas, including analgesic and anti-inflammatory, analgesic and antispasmodic, analgesics, anesthesia, antacid-antiflatulent, anti-fungal, antibiotic, anti-diabetic, anti-emetic, anti-hypertensive, anti-allergic and anti-inflammatory, anti-allergic and appetite stimulant, anticoagulant, antifibrolytic, antimalarial, anti-muscarinic, antioxidant, calcium, cardiovascular, corticosteroid, electrolytes, expectorant, haematinic, hemostatic agent, hemostatic agent with anesthetic, hormones, immunomodulator with anti-viral, muscle relaxant, narcotic analgesic, neuropathy, nutraceuticals, PPI, probiotic, reversal for muscle relaxant, sedatives, skeletal muscle relaxant, skeletal muscle relaxant and analgesic and anti-inflammatory, vasopressors, vitamins, and weight management. The company was formerly known as Themis Chemicals and changed its name to Themis Medicare Limited in 2001. Themis Medicare Limited was founded in 1952 and is headquartered in Mumbai, India.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Mumbai, India
- Employees
- 1,340
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.